Respiratory Drug Delivery VII
Respiratory Drug Delivery VII was held in Palm Harbor at Tarpon Springs, Florida from May 14 to May 18, 2000, and organized by Virginia Commonwealth University School of Pharmacy. It was the seventh in a series of international symposia concerning all aspects of drug delivery to the lung.
Over 550 attendees from around the world (Australia, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Japan, Portugal, Sweden, Switzerland, Taiwan, UK and USA) gathered in Florida for an action packed week. Academia, government, and the pharmaceutical industry were represented at this premier meeting in the world in pharmaceutical aerosols. The scientific program ran for four days, and individual sessions targeted:
- Asthma in the Third Millenium
- New Therapeutic Opportunities
- Manipulating PK & PD: Effects of Molecular Structure, Formulation and Regional Deposition
- New MDI Formulations
- Device Development: Control & Regulation
- Special Forum: Bioequivalence in Multiphase Nasal Sprays
- Progress in Drug Development
- Characterizing Aerosol Size and Deposition
- New Challenges in Aerosol Delivery Technology
The pre-prints of all podium sessions and posters were published by Serentec Press and are also available electronically on RDD Online. A complete list of all of the Scientific Poster presentations can be found in the RDD 7 Proceedings. They cover a broad selection of topics related to pulmonary and nasal drug delivery, and each one has been peer reviewed.
A special thanks to the sponsors of RDD VII 2000
3M Drug Delivery Systems, Abbott Laboratories, Aeropharm Technology, AstraZeneca, Aradigm Corporation, Battelle Pulmonary Therapeutics, Bausch & Lomb Pharmaceuticals, Bespak, Boehringer Ingelheim, Bristol Myers Squibb, CCL Pharmaceuticals, Chiesi Farmaceutici, ClinTrials BioResearch, DMV International, DuPont Fluoroproducts, Dura Pharmaceuticals, GlaxoWellcome, Hoechst Marion Roussel, Hoffman-La-Roche, Inhale Therapeutic Systems, Inspire Pharmaceuticals, Magellan Laboratories, Nastech, Novartis Pharma AG, Pamasol Willi Mader AG, Pathogenesis Corporation, Primedica Corporation, Quadrant Healthcare, Solvay Fluorides, Valois Pharma, Vectura Limited, Whitehall Robins & Wyeth Ayerst Research